The iRGD peptide demonstrates improved tumor targeting and penetration abilities via dual receptor binding (integrins and NRP‐1), while the cyclic structure of CRGDK offers enhanced stability against proteolytic degradation. The gene discussed is NRP1; the disease is neoplasm.